ZTS - Zoetis Inc.

NYSE - NYSE Delayed Price. Currency in USD
122.81
-3.64 (-2.88%)
At close: 4:03PM EDT

124.87 +2.08 (1.70%)
After hours: 4:30PM EDT

Stock chart is not supported by your current browser
Previous Close126.45
Open127.00
Bid122.80 x 900
Ask122.77 x 800
Day's Range122.45 - 127.20
52 Week Range78.90 - 130.20
Volume1,943,107
Avg. Volume1,929,404
Market Cap58.649B
Beta (3Y Monthly)0.61
PE Ratio (TTM)43.40
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.66 (0.52%)
Ex-Dividend Date2019-07-18
1y Target EstN/A
Trade prices are not sourced from all markets
  • 3 Reasons Why Zoetis (ZTS) Is a Great Growth Stock
    Zacks

    3 Reasons Why Zoetis (ZTS) Is a Great Growth Stock

    Zoetis (ZTS) could produce exceptional returns because of its solid growth attributes.

  • Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?
    Zacks

    Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?

    Is (ZTS) Outperforming Other Medical Stocks This Year?

  • Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out?
    Zacks

    Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out?

    Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • Is Zoetis Inc.'s (NYSE:ZTS) High P/E Ratio A Problem For Investors?
    Simply Wall St.

    Is Zoetis Inc.'s (NYSE:ZTS) High P/E Ratio A Problem For Investors?

    Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. To keep it practical...

  • Were Hedge Funds Right About Betting On Zoetis Inc (ZTS)?
    Insider Monkey

    Were Hedge Funds Right About Betting On Zoetis Inc (ZTS)?

    You probably know from experience that there is not as much information on small-cap companies as there is on large companies. Of course, this makes it really hard and difficult for individual investors to make proper and accurate analysis of certain small-cap companies. However, well-known and successful hedge fund managers like Jeff Ubben, George Soros […]

  • Can Zoetis (ZTS) Keep the Earnings Surprise Streak Alive?
    Zacks

    Can Zoetis (ZTS) Keep the Earnings Surprise Streak Alive?

    Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • JAZZ vs. ZTS: Which Stock Is the Better Value Option?
    Zacks

    JAZZ vs. ZTS: Which Stock Is the Better Value Option?

    JAZZ vs. ZTS: Which Stock Is the Better Value Option?

  • Zoetis Appoints Kristin Peck as New CEO, Alaix to Retire
    Zacks

    Zoetis Appoints Kristin Peck as New CEO, Alaix to Retire

    Zoetis (ZTS) names executive vice president Kristin Peck as the new CEO, effective Jan 1, 2020.

  • IDEXX's Kidney Function Test Included in IRIS Staging Views
    Zacks

    IDEXX's Kidney Function Test Included in IRIS Staging Views

    IDEXX (IDXX) is upbeat about the inclusion and approval of the SDMA-based renal care staging guidelines.

  • Here Is Hedge Funds’ 22nd Most Popular Stock Pick
    Insider Monkey

    Here Is Hedge Funds’ 22nd Most Popular Stock Pick

    Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ complex research processes to determine the best stocks to invest in. A particularly […]

  • The No. 1 Rated Pharmaceutical Company Just Named A New CEO
    Investor's Business Daily

    The No. 1 Rated Pharmaceutical Company Just Named A New CEO

    Animal-health leader Zoetis said Thursday Kristin Peck will succeed Juan Ramon Alaix as the pharma company's chief executive officer. Peck will immediately join the board of directors.

  • Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates
    Investor's Business Daily

    Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates

    Pharma companies Allergan, Bristol-Myers Squibb and Zoetis could top the Street's third-quarter earnings expectations, an analyst said Thursday. But he only expects Zoetis sales to beat.

  • 3 Healthcare Stocks to Watch for the Long Run
    TipRanks

    3 Healthcare Stocks to Watch for the Long Run

    It’s no secret that healthcare stocks have been under pressure due to geopolitical uncertainty, increased government regulation, and ongoing pressure on drug companies to lower prices. Take a look at the Biotechnology ETF (IBB) and see how badly the sector is underperforming.However, the greatest investment advice of all time comes from the Oracle of Omaha, Warren Buffett. He advised investors to be greedy when others are fearful and to be fearful when others are greedy. In short, Buffett believes the best way to make money on Wall Street is to look for quality companies that have fallen on hard times.Indeed, there are several “strong buy” stocks in the sector, which are set for significant gains in the coming months -- at least, according to Wall Street analysts. We turned to TipRanks’ Stock Screener to see which healthcare stocks these analysts believe have plenty of upside potential ahead. That’s according to the upside potential from the average analyst price target. Let’s see how that works out now: Is HCA Healthcare Stock Setting Up for a Large Move Higher?Ranked No. 67 in the 2019 Fortune 500 list as the largest United States corporations by total revenue, HCA Healthcare (HCA) manages approximately 2,000 care sites, including 184 hospitals, urgent care centers, and physician clinics, 119 freestanding surgery centers, and ER’s in the United States and United Kingdom.  This September, HCA opened a new $10 million-dollar medical facility in Orlando, Florida; its third freestanding ER launch this year, bringing the company's net worth value to $43.24 billion. In addition, HCA has started construction in partnership with the University of Central Florida on a $175 million teaching hospital, The UCF Lake Nona Medical Center, set to open in fall 2020. 5-star Wolfe analyst Justin Lake believes that a "combination of significantly lower expectations and valuation leaves an increasingly interesting risk/reward." Despite near-term uncertainty about "general lack of visibility on mix/acuity and tough comps," the analyst sees "potential that 2Q results were simply white noise, similar to UHS 1Q19, which coupled w/modest cost cuts and extra biz day in qtr. leaves potential for 3Q rebound." Lake rates HCA a Buy with $141 price target, which implies about 22% upside from current levels. (To watch Lake's track record, click here)Lake is not the only fan of the healthcare provider on Wall Street, as TipRanks analytics exhibit HCA as a Strong Buy. Based on six analysts polled by in the last three months, five rate HCA a Buy, while only one rates the stock a Hold. The 12-month average price target stands at $157.17, marking a 37% upside from where the stock is currently trading. (See HCA's price targets and analyst ratings on TipRanks) Zoetis Stock Still Has Gasoline Left in the TankWith over 65 years of experience in animal health, Zoetis (ZTS) is what many believe to be the “go-to” developer and manufacturer of medicines, vaccines, biodevices, and diagnostic products for pets and livestock. The company sells its products in more than 100 countries worldwide and now boasts over 10,000 employees; virtually dominating the global animal health market. Zoetis stock has been knocking it out of the ballpark so far this year, rising by a whopping 43%, and Wall Street analysts say there’s still some gas left in the tank.5-star Stifel analyst Jonathan Block mentioned that the company's Q2 Animal Health survey showed how well ZTS’s product pipeline is doing, having him predict an upside on the company’s 2019-2022 revenue and ESP estimates. “The Triple”, feline pain, canine pain, and feline atopic dermatitis accounted for the vast majority of pharmaceutical product innovations that Veterinarians want, all of which Zoetis could or should bring into the market over the next 1-2+ years,” Block went on to say. Block rates ZTS a 'buy' with $140 price target, which implies about 14% upside from current levels. (To watch Block's track record, click here)TipRanks reveals the veterinary drug and vaccine maker as one drawing bullish attention on Wall Street. Out of 10 analysts polled in the last 3 months, 8 rate a Buy on AMD stock, 2 maintain a Hold. The 12-month average price target stands at $137.33, marking a nearly 12% upside potential from where the stock is currently trading.(See ZTS's price targets and analyst ratings on TipRanks)Is Alexion Stock Set to Jump Over 60%?Alexion (ALXN) is a global biopharmaceutical company focusing on treatment for rare diseases through the discovery and development of advanced medical therapies. The company is best known for its development of $3 billion-a-year bestseller Soliris, a drug used to treat the rare disorders ‘atypical Hemolytic Uremic Syndrome’ (aHUS) and ‘Paroxysmal Nocturnal Hemoglobinuria’. Due to the high cost of Soliris and its niche nature, the company continues to reign undefeated in the rare diseases sector and sees high-profit margins year-over-year. In addition, Alexion recently announced that it is replacing its CFO Paul Clancy with Aradhana Sarin, M.D., the company’s chief strategy and business officer. Sarin is responsible for $2 billion in recent pipeline acquisitions and has a strong M&A background. This shift into new leadership has analysts a little excited, one would say. 5-star RBC Capital analyst Kennen MacKay reiterated an Outperform rating (i.e. Buy) on ALXN stock, stating that he sees “Dr. Sarin as a strong successor given her prior position as Senior Vice President in Business and Corporate Strategy.” Adding that Sarin “has led ALXN's business development efforts including what view as an impressive string of acquisitions and partnerships.” All in all, Alexion stock has one of the best ratings by the Street. TipRanks reveals that ALXN has a Strong Buy analyst consensus rating with 12 'buy' ratings and only one 'hold' rating in the last three months. Meanwhile the average analyst price target of $163.30 suggests the stock has upside potential of nearly 66% from the current share price for the next 12 months. (See ALXN's price targets and analyst ratings on TipRanks)

  • MarketWatch

    Zoetis names Kristin Peck as CEO effective Jan 1, replacing Juan Ramon Alaix who is retiring

    Zoetis Inc. said Thursday it has named Kristin Peck as chief executive effective Jan. 1, replacing Juan Ramon Alaix, who is retiring. Peck is currently executive vice president and group president responsible for U.S. operations, business development and strategy at the Parsippany, N.J.-based animal health company. Alaix has led the company since it was spun off from Pfizer Inc. in 2012. Shares were not yet active premarket but have gained 43% in 2019, while the S&P 500 has gained 15%.

  • TheStreet.com

    Zoetis Taps Executive VP Kristin Peck as CEO, Succeeding Juan Ramon Alaix

    Juan Ramon Alaix, CEO since 2012, is retiring. Kristin Peck currently runs U.S. operations, business development and strategy.

  • Pfizer Stock Is A Top Pharma Company — But Should You Buy It?
    Investor's Business Daily

    Pfizer Stock Is A Top Pharma Company — But Should You Buy It?

    Pfizer stock has tumbled, below other pharmaceutical stocks. Recent news has been upbeat with a drug approval and acquisitions. But the question remains: Is Pfizer stock a buy right now?

  • Call Traders Betting on More ZTS Stock Upside
    Schaeffer's Investment Research

    Call Traders Betting on More ZTS Stock Upside

    Call buying has been hot on ZTS, but call writers have focused on the October 125 call

  • Which Pharmaceutical Stocks Are Outperforming All Other Stocks?
    Investor's Business Daily

    Which Pharmaceutical Stocks Are Outperforming All Other Stocks?

    Pharmaceutical stocks slipped a single-digit percentage in the first nine months of 2019, well below their gain for 2018. Still, there are standout companies among the industry group.

  • Is Zoetis (ZTS) a Solid Growth Stock? 3 Reasons to Think " Yes "
    Zacks

    Is Zoetis (ZTS) a Solid Growth Stock? 3 Reasons to Think " Yes "

    Zoetis (ZTS) is well positioned to outperform the market, as it exhibits above-average growth in financials.

  • MoneyShow

    This REIT is Shifting to Life Science and Medical Facilities

    We are upgrading our rating on HCP Inc. (HCP) from a "hold" to a "buy" based on the company's shift in focus to life science and medical office buildings and away from senior housing and skilled nursing, observes Jacob Kilstein, editor at the indpendent Wall Street research firm, Argus Research.

  • Zoetis (ZTS) Receives EC Approval for Simparica Trio in Dogs
    Zacks

    Zoetis (ZTS) Receives EC Approval for Simparica Trio in Dogs

    Zoetis' (ZTS) leading animal health portfolio gets a boost with the approval of Simparica Trio.

  • Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed
    Investor's Business Daily

    Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed

    Biotech and pharmaceutical company stocks got no traction this week from the proposed $2 billion takeover of Alder Biopharmaceuticals or a "largely symbolic" House plan to slash drug prices.

  • ASRT vs. ZTS: Which Stock Is the Better Value Option?
    Zacks

    ASRT vs. ZTS: Which Stock Is the Better Value Option?

    ASRT vs. ZTS: Which Stock Is the Better Value Option?

  • Biotech is going to the dogs - and big profits await
    Reuters

    Biotech is going to the dogs - and big profits await

    Lescault, 43, who enrolled Moose in a clinical trial of an experimental drug designed to help his immune system fight his cancer, represents the type of pet lover that has spurred animal health companies around the globe to invest in developing complex new treatments previously reserved for humans. Biotechnology, which produces medicines from living cells, revolutionized the drug industry more than a quarter century ago with breakthrough medicines at prices that now run as high as hundreds of thousands of dollars a year.